Track Centessa Pharmaceuticals Limited — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Centessa Pharmaceuticals Limited CNTA · Stock Open Centessa Pharmaceuticals Limited in new tab

40.50 USD
EPS
-1.78
P/B
12.86
ROE
-57.38
Beta
1.12
Target Price
40.25 USD
Loading chart...
Key Metrics
EPS-1.78
Book Value3.15
Price to Book12.86
Debt/Equity24.33
% Insiders0.670%
Estimates
Forward P/E-22.75
Forward EPS-1.78
Target Mean Price40.25

DCF valuation

Model fair value for Centessa Pharmaceuticals Limited (CNTA)
Result
Sign in to run the valuation for CNTA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 40.25 USD (low 38.00, high 45.00)
Low 38.00
Mean 40.25
High 45.00
Price 40.50
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Centessa Pharmaceuticals Limited Logo Centessa Pharmaceuticals Limited Analysis (CNTA)

United Kingdom Health Care Official Website Stock

Is Centessa Pharmaceuticals Limited a good investment? Centessa Pharmaceuticals Limited (CNTA) is currently trading at 40.50 USD. Market analysts have a consensus price target of 40.25 USD. This suggests the asset is currently trading above analyst expectations.

Investor FAQ

Does Centessa Pharmaceuticals Limited pay a dividend?

No, it does not currently pay a dividend.

What asset class is Centessa Pharmaceuticals Limited?

Centessa Pharmaceuticals Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Exchange Ticker
NMS (United States) CNTA
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2026
38.00 USD
June 24, 2026 38.0000
Upcoming Dividends
Name Payment Date Status Amount
Centessa Pharmaceuticals Limited Jun 24, 2026 38.0 USD
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion